Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Coherus Oncology, Inc. - Common Stock (NQ:CHRS)

0.8300 +0.0243 (+3.02%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Coherus Oncology, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stocks That Hit 52-Week Lows On Friday
  On Friday, 63 companies hit new 52-week lows. 
Via Benzinga
Coherus Prices Public Offering of Common Stock
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus BioSciences Earnings Preview
Via Benzinga
Coherus BioSciences's Return On Capital Employed Overview
Via Benzinga
A Preview Of Coherus BioSciences's Earnings
Via Benzinga
Vodafone, Calliditas Therapeutics, Rumble And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures traded mixed this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Coherus Announces Proposed Public Offering of Common Stock
From Coherus BioSciences, Inc.
Via GlobeNewswire
Gold Edges Higher; PayPal Shares Tumble Despite Upbeat Earnings
U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite dropping around 50 points on Tuesday. The Dow traded down 0.01% to 33,616.00 while the NASDAQ fell 0.43% to... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why PRA Group Shares Are Trading Lower By 44%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers TScan Therapeutics, Inc. (NASDAQ: TCRX) shares gained 118% to $4.68 after the company and Amgen announced collaboration to identify novel targets in Crohn's disease. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We're starting off the day with the biggest pre-market stock movers traders will want to keep in mind while trading on Tuesday! 
Via InvestorPlace
Coherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus BioSciences to Present at Upcoming Investor Conferences in May
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus BioSciences to Report First Quarter 2023 Financial Results on May 8, 2023
From Coherus BioSciences, Inc.
Via GlobeNewswire
Analyst Sees A Multibagger, Initiates Coverage On This 'Top Notch Biosimilar Business'
Truist initiated coverage on Coherus BioSciences Inc (NASDAQ: CHRS) with a Buy rating and a  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 1, 2023
Via Benzinga
Coherus and Junshi Biosciences Announce Toripalimab Studies to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From Coherus BioSciences, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For March 28, 2023
Via Benzinga
PVH, First Republic Bank And Other Big Stocks Moving Higher In Tuesday's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Coherus BioSciences Reports Fourth Quarter and Full Year 2022 Results
From Coherus BioSciences, Inc.
Via GlobeNewswire
FDA Approves UDENYCA® Autoinjector
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus BioSciences to Present at Upcoming Investor Conferences in March
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus BioSciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023
From Coherus BioSciences, Inc.
Via GlobeNewswire
Week In Review: China Biopharmas Announce Three Out-Licensing Deals Totaling $2 Billion
Jiangsu Hengrui Pharma out-licensed US rights for a novel small molecule EZH2 inhibitor in a $706 million agreement with Treeline Biosciences of Connecticut. Hengrui will receive an upfront payment of... 
Via Talk Markets
Coherus and Junshi Biosciences Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma
Final overall survival analysis of the JUPITER-02 trial shows first-line treatment with toripalimab plus chemotherapy significantly prolongs survival in patients with advanced NPC 
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Granted Permanent, Product-Specific Q-Code for CIMERLI® (ranibizumab-eqrn) from the Centers for Medicare and Medicaid Services
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus BioSciences Announces New Employment Inducement Grants
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea® Biosimilar FYB203 from Klinge Biopharma
Additional Growth Driver Projected to Significantly Increase Mid-to-Long Term Revenue Potential 
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus BioSciences Management to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Coherus BioSciences, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.